Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 5Lymphoma, Large-Cell, Anaplastic 2Brain Neoplasms 2Sexual Dysfunction, Physiological 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1NSCLC 1Meningioma 1Granuloma, Plasma Cell 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Ependymoma 1Disease Progression 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 21pembrolizumab 16Gemcitabine 16Paclitaxel 15Radiotherapy 14Carboplatin 14Radiotherapy, Intensity-Modulated 13Cyclophosphamide 9Cetuximab 9Magnetic Resonance Spectroscopy 8Radiation 7padeliporfin 6Specimen Handling 6Oxaliplatin 6Fluorouracil 6Drug Therapy 6Docetaxel 6Capecitabine 6Bevacizumab 6anlotinib 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Celecoxib 5poly ICLC 4fludarabine 4Standard of Care 4Sorafenib 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma × brigatinib × Clear all
NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡